**SUBSECTION E.1: IIH ENDOCRINE-METABOLIC / 11β-HSD1 / ANDROGEN &
OBESITY AXIS**

STUDY_ID,FIRST_AUTHOR,YEAR,JOURNAL,ARTICLE_TYPE,STUDY_DESIGN,POPULATION_TYPE,N_IIH,N_CONTROL,ASSOCIATION_ID,ROW_TYPE,EXPOSURE_TYPE,EXPOSURE_NAME_AS_REPORTED,OUTCOME_TYPE,OUTCOME_NAME_AS_REPORTED,COMPARISON_TYPE,DATA_TYPE,GROUP1_LABEL,GROUP1_MEAN,GROUP1_SD,GROUP1_N,GROUP2_LABEL,GROUP2_MEAN,GROUP2_SD,GROUP2_N,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,DIRECTION_SUMMARY_TEXT,EVIDENCE_LEVEL_AS_REPORTED,RELEVANCE_FOR_ENDOCRINE_MODEL_TEXT,PDF_SOURCE_IDENTIFIER

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,70,100,A01,OriginalNumericAssociation,Serum_Androgen,T
(nmol/l),IIH_vs_Control,IIH vs Simple
Obesity,IIH_vs_Controls,Continuous,IIH,1.7,1.0,70,Simple
Obesity,1.0,0.5,40,Ratio,NR,NR,NR,\<0.001,\"Serum Testosterone
significantly higher in IIH vs BMI-matched obese controls. Data Median
(IQR).\",NR,\"Quantifies androgen excess in
IIH.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,70,60,A02,OriginalNumericAssociation,Serum_Androgen,T
(nmol/l),IIH_vs_Control,IIH vs
PCOS,IIH_vs_Controls,Continuous,IIH,1.7,1.0,70,PCOS,1.2,0.5,60,Ratio,NR,NR,NR,\<0.001,\"Serum
Testosterone significantly higher in IIH vs BMI-matched PCOS controls.
Data Median (IQR).\",NR,\"Differentiates IIH androgen profile from
PCOS.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,70,60,A03,OriginalNumericAssociation,Serum_Androgen,A4
(nmol/l),IIH_vs_Control,IIH vs
PCOS,IIH_vs_Controls,Continuous,IIH,2.4,1.4,70,PCOS,5.7,4.3,60,Ratio,NR,NR,NR,\<0.001,\"Serum
Androstenedione significantly LOWER in IIH vs BMI-matched PCOS controls.
Data Median (IQR).\",NR,\"Differentiates IIH androgen profile from
PCOS.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,70,100,A04,OriginalNumericAssociation,Serum_Androgen,11KA4
(nmol/l),IIH_vs_Control,IIH vs
PCOS/Obesity,IIH_vs_Controls,Continuous,IIH,0.4,0.2,13,PCOS,12.1,6.6,20,Ratio,NR,NR,NR,\<0.001,\"Serum
11-oxygenated androgens (11KA4) not elevated in IIH, unlike in
PCOS.\",NR,\"Rules out adrenal androgen pathway in
IIH.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,40,45,A05,OriginalNumericAssociation,Androgen_Index,5aTHF/THF
ratio,IIH_vs_Control,IIH vs
PCOS/Obesity,IIH_vs_Controls,Continuous,IIH,1.2,0.8,40,PCOS,0.9,0.7,30,Ratio,NR,NR,NR,\<0.05,\"Systemic
5a-reductase activity (androgen activation) increased in IIH vs
controls. Data Median (IQR).\",NR,\"Suggests increased androgen
activation in
IIH.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,55,50,A06,OriginalNumericAssociation,CSF_Androgen,CSF
T,IIH_vs_Control,IIH vs Lean/Obese
Controls,IIH_vs_Controls,Continuous,IIH,NR,NR,55,Obese
Controls,NR,NR,19,Ratio,NR,NR,NR,\<0.0001,\"CSF Testosterone
significantly higher in IIH vs lean and obese controls. (Median \~0.05
vs \~0.02 nmol/l).\",NR,\"Confirms androgen excess within the CSF
compartment.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,55,50,A07,OriginalNumericAssociation,CSF_Androgen,CSF
A4,IIH_vs_Control,IIH vs Lean/Obese
Controls,IIH_vs_Controls,Continuous,IIH,NR,NR,55,Obese
Controls,NR,NR,19,Ratio,NR,NR,NR,\<0.0001,\"CSF Androstenedione
significantly higher in IIH vs lean and obese controls. (Median \~5 vs
\~1 nmol/l).\",NR,\"Confirms precursor androgen excess in
CSF.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,MechanisticClinical,Lab
mechanistic,IIH_vs_Control,NR,NR,A08,OriginalNumericAssociation,Other,AR
(mRNA),GeneExpression,AR mRNA expression,Other,Continuous,Choroid
plexus,NR,NR,5,Adrenal,NR,NR,3,Other,NR,NR,NR,NR,\"Human choroid plexus
expresses Androgen Receptor (AR) and activating enzyme
AKR1C3.\",NR,\"Establishes CP as an androgen-responsive
tissue.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,MechanisticClinical,Lab
mechanistic,PreclinicalModel,NR,NR,A09,OriginalNumericAssociation,Serum_Androgen,Testosterone
(100 nM),TransporterActivity,Na+/K+-ATPase activity
(AUC),Pre_vs_Post_Treatment,Continuous,Testosterone,0.77,0.59,39,Vehicle,0.56,0.28,39,MD,NR,NR,NR,\<0.01,\"Testosterone
significantly increased Na+/K+-ATPase activity (AUC) in rat CP cell line
(Z310).\",NR,\"Links androgens to CSF secretion mechanism
(NKA).\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

OReilly_2019_JCIInsight,O\'Reilly,2019,JCI
Insight,MechanisticClinical,Lab
mechanistic,PreclinicalModel,NR,NR,A10,OriginalNumericAssociation,Serum_Androgen,Testosterone
(100 nM),GeneExpression,Car2 (Carbonic Anhydrase II)
mRNA,Pre_vs_Post_Treatment,Continuous,Testosterone,NR,NR,3,Vehicle,NR,NR,3,Other,NR,NR,NR,\<0.05,\"Testosterone
significantly upregulated Car2 (Carbonic Anhydrase) mRNA in rat CP cell
line.\",NR,\"Links androgens to CA
pathway.\",125348.2-20220414102210-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,Obesity,IIH_Risk,EndocrineMetabolic,\"IIH
is recognized as a systemic metabolic disorder, not just a CNS
disorder.\",NR,No,NR,Frames IIH as a systemic metabolic
disease.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,Serum_Androgen,IIH_vs_Control,EndocrineMetabolic;Testosterone,IIH
patients show a distinct profile of androgen excess.,NR,Yes,O\'Reilly
2019,Supports androgen excess hypothesis.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,Leptin,IIH_vs_Control,EndocrineMetabolic;Leptin,IIH
patients show adipocyte leptin overproduction and
hyperleptinemia.,NR,Yes,Westgate 2021,Supports leptin resistance
hypothesis.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,11bHSD1,IIH_vs_Control,EndocrineMetabolic;11bHSD1;Cortisol,\"Targeted
blockade of 11β-HSD1 has demonstrated therapeutic
potential.\",NR,Yes,Markey 2020,Identifies 11b-HSD1 as therapeutic
target.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,GLP1RA,ICP,Treatment;GLP1R,\"GLP-1R
agonists (exendin-4) caused rapid and sustained ICP decrease, even
without weight loss.\",NR,Yes,Mitchell 2023,Identifies GLP-1RA as
therapeutic target.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A06,ReviewDirectionalSummary,Serum_Androgen,CSF_Production,ChoroidPlexus;NaK-ATPase;NKCC1,\"Testosterone
may increase CSF production by upregulating Na+/K+-ATPase and NKCC1
activity.\",NR,Yes,O\'Reilly 2019,Hypothesizes androgen mechanism on CSF
secretion.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A07,ReviewDirectionalSummary,Obesity,ICP,VenousOutflow;CVP,\"Obesity
can increase intra-abdominal pressure, raising CVP and impairing
cerebral venous outflow.\",NR,No,NR,Posits mechanical (obesity)
mechanism for ICP.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A08,ReviewDirectionalSummary,Vitamin_B12,IIH_Risk,Micronutrient,\"Micronutrient
deficiencies (Vit A, Vit B12, folate, iron) are prevalent in obesity and
linked to IIH.\",NR,No,NR,Links micronutrients (B12) to IIH
risk.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A09,ReviewDirectionalSummary,Other,Headache,Metabolomics,\"Altered
arginine metabolism (impaired NO synthesis) may be associated with
severe headache phenotype.\",NR,Yes,Mulla 2015,Links headache to
metabolic byproducts.,ad-16-6-3311.pdf

Li_2025_AgingDis,Li,2025,Aging
Dis,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A10,ReviewDirectionalSummary,Other,Headache,Metabolomics,\"Elevated
CSF acetate levels correlate positively with headache
severity.\",NR,Yes,Grech 2022,Links headache to metabolic
byproducts.,ad-16-6-3311.pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A01,OriginalNumericAssociation,Leptin,CSF
leptin
(ng/mL),IIH_vs_Control,Continuous,IIH,3.9,1.7,23,Controls,1.4,0.9,24,MD,2.5,NR,NR,\<0.001,\"CSF
leptin significantly higher in IIH (3.9 ng/mL) vs controls (1.4 ng/mL),
p\<0.001.\",NR,\"Quantifies elevated CSF leptin in IIH.\",Clinical
Endocrinology - 2009 - Ball - Elevated cerebrospinal fluid CSF leptin in
idiopathic intracranial hypertension .pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A02,OriginalNumericAssociation,Leptin,Serum
leptin
(ng/mL),IIH_vs_Control,Continuous,IIH,55.1,25.2,23,Controls,40.4,22.3,24,MD,14.7,NR,NR,0.05,\"Serum
leptin higher in IIH (55.1 ng/mL) vs controls (40.4 ng/mL),
p=0.05.\",NR,\"Quantifies elevated serum leptin in IIH.\",Clinical
Endocrinology - 2009 - Ball - Elevated cerebrospinal fluid CSF leptin in
idiopathic intracranial hypertension .pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A03,OriginalNumericAssociation,Leptin,CSF:serum
leptin
ratio,IIH_vs_Control,Continuous,IIH,0.076,0.03,23,Controls,0.038,0.02,24,MD,0.038,NR,NR,\<0.001,\"CSF:serum
leptin ratio significantly higher in IIH, suggesting impaired transport
or resistance.\",NR,\"Establishes central leptin resistance.\",Clinical
Endocrinology - 2009 - Ball - Elevated cerebrospinal fluid CSF leptin in
idiopathic intracranial hypertension .pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A04,OriginalNumericAssociation,Leptin,CSF
leptin,Adiposity,Exposure_vs_ContinuousOutcome,Continuous,NR,NR,NR,NR,NR,NR,NR,NR,Correlation
(r),0.86,NR,NR,\<0.001,\"CSF leptin strongly correlated with BMI
(r=0.86) across all subjects.\",NR,\"Links CSF leptin directly to
BMI.\",Clinical Endocrinology - 2009 - Ball - Elevated cerebrospinal
fluid CSF leptin in idiopathic intracranial hypertension .pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A05,OriginalNumericAssociation,Leptin,CSF
leptin,ICP_or_CSFPressure,Exposure_vs_ContinuousOutcome,Continuous,NR,NR,NR,NR,NR,NR,NR,NR,Correlation
(r),0.17,NR,NR,0.3,\"CSF leptin did NOT correlate with ICP (r=0.17,
p=0.3).\",NR,\"Decouples CSF leptin from ICP measurement.\",Clinical
Endocrinology - 2009 - Ball - Elevated cerebrospinal fluid CSF leptin in
idiopathic intracranial hypertension .pdf

Ball_2009_ClinEndocrinol,Ball,2009,Clin Endocrinol
(Oxf),OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,23,24,A06,OriginalNumericAssociation,Leptin,CSF
leptin,VisualFunction,Exposure_vs_ContinuousOutcome,Continuous,NR,NR,NR,NR,NR,NR,NR,NR,Correlation
(r),-0.06,NR,NR,0.7,\"CSF leptin did NOT correlate with visual field PMD
(r=-0.06, p=0.7).\",NR,\"Decouples CSF leptin from visual
outcome.\",Clinical Endocrinology - 2009 - Ball - Elevated cerebrospinal
fluid CSF leptin in idiopathic intracranial hypertension .pdf

K_2023_Biomedicines,K.,2023,Biomedicines,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,Vitamin_B12,IIH_Risk,Micronutrient,\"Reviews
case reports suggesting an association between Vitamin B12 deficiency
and IIH.\",NR,No,NR,\"Links B12 deficiency to IIH
risk.\",biomedicines-11-01461.pdf

K_2023_Biomedicines,K.,2023,Biomedicines,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,Vitamin_B12,IIH_Risk,Micronutrient;Obesity,\"Vitamin
B12 deficiency is common in obesity, a primary risk factor for
IIH.\",NR,No,NR,\"Identifies B12 deficiency as comorbidity of
obesity.\",biomedicines-11-01461.pdf

K_2023_Biomedicines,K.,2023,Biomedicines,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,Vitamin_B12,IIH_Risk,Micronutrient;Homocysteine;VenousOutflow,\"B12
deficiency can cause hyperhomocysteinemia, a risk factor for cerebral
venous sinus thrombosis (CVST).\",NR,No,NR,\"Proposes B12 deficiency -\>
CVST -\> IIH pathway.\",biomedicines-11-01461.pdf

K_2023_Biomedicines,K.,2023,Biomedicines,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,Vitamin_B12,IIH_Risk,Metformin;PCOS,\"Metformin
(used for obesity/PCOS) is a known cause of B12 deficiency, acting as a
confounder.\",NR,No,NR,\"Identifies Metformin/PCOS/B12
interaction.\",biomedicines-11-01461.pdf

Hornby_2018_Neuroophthalmology,Hornby,2018,Neuro-ophthalmology,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,25,16,A01,OriginalNumericAssociation,DXA_Adiposity,Trunk
fat %,Adiposity,IIH_vs_Controls,Continuous,IIH,48.9,4.5,25,Obese
Controls,44.1,6.5,16,MD,4.8,NR,NR,0.003,\"IIH patients had significantly
higher trunk fat % than BMI-matched obese controls.\",NR,\"Confirms IIH
fat distribution is centrally dominant.\",hornby2018.pdf

Hornby_2018_Neuroophthalmology,Hornby,2018,Neuro-ophthalmology,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,25,16,A02,OriginalNumericAssociation,DXA_Adiposity,Android
fat %,Adiposity,IIH_vs_Controls,Continuous,IIH,52.0,3.9,25,Obese
Controls,47.9,5.6,16,MD,4.1,NR,NR,0.006,\"IIH patients had significantly
higher android fat % than obese controls.\",NR,\"Confirms IIH fat
distribution is centrally dominant.\",hornby2018.pdf

Hornby_2018_Neuroophthalmology,Hornby,2018,Neuro-ophthalmology,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,25,16,A03,OriginalNumericAssociation,Adiposity_Index,Android/Gynoid
ratio,Adiposity,IIH_vs_Controls,Continuous,IIH,0.94,0.06,25,Obese
Controls,0.90,0.06,16,MD,0.04,NR,NR,0.022,\"IIH patients had a
significantly higher (more central) Android/Gynoid fat
ratio.\",NR,\"Confirms IIH fat distribution is centrally
dominant.\",hornby2018.pdf

Hornby_2018_Neuroophthalmology,Hornby,2018,Neuro-ophthalmology,OriginalCohort,Cross-sectional
case-control,IIH_vs_Control,25,16,A04,OriginalNumericAssociation,DXA_Adiposity,Trunk
fat
%,ICP_or_CSFPressure,Exposure_vs_ContinuousOutcome,Continuous,NR,NR,NR,NR,NR,NR,NR,NR,Correlation
(r),0.17,NR,NR,0.4,\"Trunk fat % did not correlate with ICP in the IIH
group.\",NR,\"Decouples fat distribution from simple ICP
levels.\",hornby2018.pdf

Markey_2016_JPainRes,Markey,2016,J Pain
Res,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,Obesity,IIH_Risk,EndocrineMetabolic;Obesity,Obesity
is the main risk factor for IIH; 90% of patients are
obese.,NR,No,NR,Confirms obesity as primary risk factor.,nihms666090.pdf

Markey_2016_JPainRes,Markey,2016,J Pain
Res,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,Glucocorticoids,IIH_Risk,EndocrineMetabolic;11bHSD1;Cortisol,\"IIH
is linked to global increase in 11β-HSD1 activity (cortisol activation),
beyond simple obesity.\",NR,No,NR,\"Links IIH to 11β-HSD1
hyperactivity.\",nihms666090.pdf

Markey_2016_JPainRes,Markey,2016,J Pain
Res,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,11bHSD1,CSF_Production,ChoroidPlexus;NaK-ATPase,\"11β-HSD1
is expressed in human choroid plexus; cortisol may regulate CSF
secretion via Na+/K+-ATPase.\",NR,No,NR,\"Proposes 11β-HSD1/cortisol
mechanism on CP.\",nihms666090.pdf

Markey_2016_JPainRes,Markey,2016,J Pain
Res,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,AndrogenExcess,IIH_Risk,EndocrineMetabolic;Androgens,\"IIH
is associated with androgen excess (testosterone).\",NR,Yes,O\'Reilly
2019 (in progress),Links IIH to androgen excess.,nihms666090.pdf

Markey_2016_JPainRes,Markey,2016,J Pain
Res,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,11bHSD1,ICP,Treatment;Preclinical,11β-HSD1
inhibitors lower ICP in preclinical models.,NR,No,NR,\"Supports 11β-HSD1
as therapeutic target.\",nihms666090.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,11bHSD1,IIH_vs_Control,EndocrineMetabolic;11bHSD1;Cortisol,\"IIH
is associated with increased global 11β-HSD1 activity, distinct from
simple obesity.\",NR,Yes,Westgate 2021,Positions IIH as 11β-HSD1
dysfunction.,s11910-025-01420-y.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,11bHSD1,CSF_Production,ChoroidPlexus;NaK-ATPase,\"11β-HSD1
is expressed in CP; cortisol (its product) upregulates Na+/K+-ATPase
activity.\",NR,Yes,Westgate 2022 (Thesis),Defines mechanism for 11β-HSD1
on CSF secretion.,s11910-025-01420-y.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewNumericSummary,11bHSD1,ICP_or_CSFPressure,Treatment;RCT,AZD4017
(11β-HSD1 inhibitor) reduced ICP by -4.3 cmH2O (vs -1.4 placebo) at 12
weeks.,NR,Yes,IIH:DT (Markey 2020),Quantifies 11β-HSD1 inhibitor effect
on ICP.,s11910-025-01420-y.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,11bHSD1,Adiposity,EndocrineMetabolic;Obesity,\"11β-HSD1
activity is increased in subcutaneous adipose tissue (SAT) in
obesity.\",NR,No,NR,Links 11β-HSD1 to obesity
phenotype.,s11910-025-01420-y.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,GLP1RA,11bHSD1,EndocrineMetabolic;GLP1R,\"GLP-1R
agonists can reduce 11β-HSD1 expression in adipose
tissue.\",NR,No,NR,\"Links GLP-1RA and 11β-HSD1
pathways.\",s11910-025-01420-y.pdf

A_2025_JEndocrinolInvest,A.,2025,J Endocrinol
Invest,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A06,ReviewDirectionalSummary,AndrogenExcess,11bHSD1,EndocrineMetabolic;Androgens,\"IIH
features both androgen excess and 11β-HSD1 hyperactivity, which are
interconnected.\",NR,Yes,O\'Reilly 2019,Connects the two main endocrine
hypotheses.,s11910-025-01420-y.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,GLP1RA,ICP;Headache,Treatment;RCT,\"Phase
2 trial (IIH:E) showed Exenatide (GLP-1RA) significantly reduced ICP and
headache days.\",High,Yes,IIH:E (Mitchell 2023),Confirms clinical
efficacy of GLP-1RA.,s12987-022-00348-6.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,GLP1RA,CSF_Production;ICP,ChoroidPlexus;GLP1R;Preclinical,\"GLP-1R
agonists lower ICP in preclinical models (healthy and hydrocephalic
rats).\",NR,Yes,Botfield 2017,Establishes preclinical
rationale.,s12987-022-00348-6.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,GLP1RA,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"GLP-1R
is expressed in choroid plexus; agonists inhibit Na+/K+-ATPase
activity.\",NR,Yes,Botfield 2017; Westgate 2022 (Thesis),Defines
mechanism (NKA inhibition).,s12987-022-00348-6.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,GLP1RA,Weight,Treatment;WeightLoss,\"GLP-1R
agonists also promote weight loss, addressing the primary IIH risk
factor.\",NR,No,NR,Highlights dual benefit (ICP +
weight).,s12987-022-00348-6.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,Acetazolamide,TransporterActivity,ChoroidPlexus;NaK-ATPase;CAI,\"Acetazolamide
(100uM) does NOT inhibit Na+/K+-ATPase activity in CP
cells.\",NR,Yes,Westgate 2023,Contrasts ACZ mechanism from
GLP-1RA.,s12987-022-00348-6.pdf

Botfield_2022_FluidsBarriersCNS,Botfield,2022,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A06,ReviewDirectionalSummary,Topiramate,CSF_Production,ChoroidPlexus;CAI,\"Topiramate
(100uM) inhibits CSF secretion (NKA-independent mechanism) in ex vivo
CP.\",NR,Yes,Westgate 2023,Notes TPM inhibits secretion via different
path.,s12987-022-00348-6.pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,Obesity,IIH_Risk,EndocrineMetabolic;Obesity,\"Obesity
is the main risk factor for IIH; prevalence is rising with obesity
epidemic.\",NR,No,NR,Confirms obesity as primary risk
factor.,s12987-023-00436-1 (1).pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,DXA_Adiposity,Adiposity,EndocrineMetabolic;Obesity;TrunkFat,\"IIH
patients have increased truncal/android fat mass compared to BMI-matched
controls.\",NR,Yes,Hornby 2018,Defines central obesity
phenotype.,s12987-023-00436-1 (1).pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,11bHSD1,IIH_vs_Control,EndocrineMetabolic;Cortisol,\"IIH
associated with increased systemic 11β-HSD1 activity (cortisol
generation).\",NR,Yes,Sinclair 2010; Markey 2016,Links 11β-HSD1
hyperactivity to IIH.,s12987-023-00436-1 (1).pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,11bHSD1,CSF_Production,ChoroidPlexus;NaK-ATPase,\"11β-HSD1
is expressed in CP; cortisol (its product) upregulates Na+/K+-ATPase
activity.\",NR,Yes,Westgate 2022 (Thesis),Defines mechanism for 11β-HSD1
on CSF secretion.,s12987-023-00436-1 (1).pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,11bHSD1,ICP,Treatment;RCT,Phase
2 RCT (IIH:DT) showed 11β-HSD1 inhibitor AZD4017 significantly reduced
ICP.,High,Yes,IIH:DT (Markey 2020),Confirms 11β-HSD1 inhibitor
efficacy.,s12987-023-00436-1 (1).pdf

Westgate_2023_FluidsBarriersCNS,Westgate,2023,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A06,ReviewDirectionalSummary,WeightLoss,11bHSD1,EndocrineMetabolic;Treatment,\"Weight
loss (diet or bariatrics) reduces 11β-HSD1 activity, linking the two
treatments.\",NR,No,NR,Connects weight loss to 11β-HSD1
mechanism.,s12987-023-00436-1 (1).pdf

OReilly_2024_FluidsBarriersCNS,O\'Reilly,2024,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A01,ReviewNumericSummary,Serum_Androgen,Testosterone,IIH_vs_Control,\"IIH
women have elevated serum and CSF testosterone vs matched controls
(obese and PCOS).\",NR,Yes,O\'Reilly 2019,Reiterates androgen excess
finding.,s12987-024-00582-0.pdf

OReilly_2024_FluidsBarriersCNS,O\'Reilly,2024,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,Serum_Androgen,Other,ChoroidPlexus;AR;AKR1C3,\"Human
choroid plexus expresses Androgen Receptor (AR) and androgen-activating
enzyme AKR1C3.\",NR,Yes,O\'Reilly 2019,Confirms CP is androgen
target.,s12987-024-00582-0.pdf

OReilly_2024_FluidsBarriersCNS,O\'Reilly,2024,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,Serum_Androgen,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"Testosterone
increases Na+/K+-ATPase activity in rat choroid plexus
cells.\",NR,Yes,O\'Reilly 2019; Westgate 2022,Links androgens to NKA
(CSF secretion).,s12987-024-00582-0.pdf

OReilly_2024_FluidsBarriersCNS,O\'Reilly,2024,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,Serum_Androgen,GeneExpression,ChoroidPlexus;CAII;CAIII,\"Testosterone
increases expression of Carbonic Anhydrases (Car2, Car3) in rat CP
cells.\",NR,Yes,Westgate 2022; O\'Reilly 2019,Links androgens to CA
pathway.,s12987-024-00582-0.pdf

OReilly_2024_FluidsBarriersCNS,O\'Reilly,2024,Fluids Barriers
CNS,NarrativeReview,Review,IIH_only,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,Serum_Androgen,TransporterActivity,ChoroidPlexus;NKCC1,\"Testosterone
increases NKCC1 activity in CP cells, suggesting modulation of CSF
secretion.\",NR,Yes,Westgate 2022,Links androgens to NKCC1 (CSF
secretion).,s12987-024-00582-0.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A01,ReviewDirectionalSummary,GLP1RA,Other,ChoroidPlexus;GLP1R,\"GLP-1R
protein expression is confirmed in human and rat choroid plexus
epithelial cells.\",NR,No,NR,Confirms target location for
GLP-1RA.,Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A02,ReviewDirectionalSummary,GLP1RA,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"GLP-1R
agonists (Exendin-4) inhibit Na+/K+-ATPase activity in CP
cells.\",NR,No,NR,\"Defines GLP-1RA mechanism (NKA
inhibition).\",Investigation into the Choroid Plexus Molecular
Mechanisms Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A03,ReviewDirectionalSummary,11bHSD1,Other,ChoroidPlexus;11bHSD1,\"11β-HSD1
expression and activity is confirmed in human and rat choroid
plexus.\",NR,No,NR,\"Confirms target location for
11β-HSD1.\",Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A04,ReviewDirectionalSummary,Cortisol,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"Cortisol
(product of 11β-HSD1) increases Na+/K+-ATPase activity in CP
cells.\",NR,No,NR,\"Defines mechanism for 11β-HSD1 on CSF
secretion.\",Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A05,ReviewDirectionalSummary,11bHSD1,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"11β-HSD1
inhibitors (AZD4017) block the cortisol-driven increase in Na+/K+-ATPase
activity.\",NR,No,NR,\"Defines mechanism of 11β-HSD1
inhibitors.\",Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A06,ReviewDirectionalSummary,Serum_Androgen,Other,ChoroidPlexus;AR;AKR1C3,\"Androgen
Receptor (AR) and AKR1C3 (activating enzyme) expression confirmed in
human/rat CP.\",NR,Yes,O\'Reilly 2019,Confirms CP is androgen target
tissue.,Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A07,ReviewDirectionalSummary,Serum_Androgen,TransporterActivity,ChoroidPlexus;NaK-ATPase,\"Testosterone
significantly increases Na+/K+-ATPase activity in CP
cells.\",NR,Yes,O\'Reilly 2019,Links androgens to NKA (CSF
secretion).,Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A08,ReviewDirectionalSummary,Serum_Androgen,GeneExpression,ChoroidPlexus;CAII;CAIII,\"Testosterone
significantly increases mRNA of Car2 and Car3 (Carbonic
Anhydrases).\",NR,Yes,O\'Reilly 2019,Links androgens to CA
pathway.,Investigation into the Choroid Plexus Molecular Mechanisms
Underlying Idiopathic Intracranial Hypertension.pdf

Westgate_2022_Thesis,Westgate,2022,Thesis,Thesis,Preclinical;
IIH,general_IIH,EndocrineMetabolic,A09,ReviewDirectionalSummary,Serum_Androgen,TransporterActivity,ChoroidPlexus;NKCC1,\"Testosterone
significantly increases NKCC1 activity in CP cells.\",NR,No,NR,Links
androgens to NKCC1 (CSF secretion).,Investigation into the Choroid
Plexus Molecular Mechanisms Underlying Idiopathic Intracranial
Hypertension.pdf
